Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pulse Biosciences CS (NQ: PLSE )

17.68 +1.56 (+9.68%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Pulse Biosciences CS

< Previous 1 2 3 4 5 Next >
Pulse Biosciences Announces Positive Clinical Data Presented at the American Thyroid Association
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences Reports Business Updates and Third Quarter 2024 Financial Results
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences Announces Appointment of David Kenigsberg, M.D. as Chief Medical Officer of Electrophysiology
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences Schedules Third Quarter 2024 Financial Results Conference Call for October 30, 2024
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences Reports Business Updates and Preliminary Second Quarter 2024 Financial Results
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences, Inc. Appoints Paul LaViolette to Its Board of Directors
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences, Inc. Announces Successful Treatment of Patients in First-in-Human Study with its Nano-PFA Cardiac Surgery System
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences, Inc. Announces Participation in Upcoming Investor Conferences
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences Schedules Second Quarter 2024 Financial Results Conference Call for August 12, 2024
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences, Inc. Announces Receipt of FDA Breakthrough Device Designation for CellFX® nsPFA Cardiac Surgery System for the Treatment of Atrial Fibrillation
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences, Inc. Announces the Closing of its Rights Offering
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences, Inc. Announces Preliminary Results for its Rights Offering
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences Announces Updated Timing of Rights Offering for Up to $60,000,000
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences’ CellFX Nanosecond Pulsed Field Ablation (nsPFA™) Technology to be Featured in Several Presentations at The Heart Rhythm Society 2024 Annual Meeting
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences Enhances Executive Leadership Team
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences Announces First U.S. Procedure with the CellFX nsPFA Percutaneous Electrode System
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences Reports Business Updates and First Quarter 2024 Financial Results
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences Announces Timing of Rights Offering for Up to $60,000,000
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences Schedules First Quarter 2024 Financial Results Conference Call for May 7, 2024
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2023 Financial Results
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences Announces Plans to Initiate a Rights Offering
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences Schedules Fourth Quarter & Full Year 2023 Financial Results Conference Call for March 28, 2024
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences Announces FDA 510(k) Clearance for its CellFX® nsPFA™ Percutaneous Electrode System
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences Announces Positive 60-Day Follow-Up Evaluations for Initial Patients treated in the CellFX® nsPFA™ 360° Cardiac Catheter First-in-Human Feasibility Study
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences Announces Preliminary Findings from its CellFX nsPFA 360 Cardiac Catheter First-In-Human Feasibility Study to be Featured in Podium Presentation at the AF Symposium
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences Files 510(k) Submission with U.S. FDA for its CellFX® nsPFA™ Cardiac Clamp
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences Announces First-in-Human Procedures with its Novel CellFX™ Nanosecond Pulsed Field Ablation (nsPFA™) Cardiac Catheter
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences Files 510(k) Submission with U.S. FDA for its CellFX nsPFA Percutaneous Electrode
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences to Present at the 35th Annual Piper Sandler Healthcare Conference
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences Reports Business Updates and Third Quarter 2023 Financial Results
From Pulse Biosciences, Inc.
Via Business Wire
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.